British journal of haematology · 2020
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McLornan Donal P, Malpassuti Vittoria, Lippinkhof-Kozijn Anne, Potter Victoria, Beelen Dietrich, Bunjes Donald, Sengeloev Henrik, Radujkovic Aleksandar, Passweg Jakob, Chalandon Yves, Kröger Nicolaus, Wulf Gerald G, Johansson Jan-Erik, Ciceri Fabio, Bornhäuser Martin, Holler Ernst, Guffroy Blandine, Martin Sonja, Neubauer Andreas, Gramatski Martin, Robin Marie, Iacobelli Simona, Hayden Patrick, Hernández Boluda Juan C, Czerw Tomasz, Yakoub-Agha Ibrahim
Аннотация
Myeloproliferative Neoplasm (MPN), unclassifiable (MPN-U) is a heterogeneous disease with regards to both clinical phenotype and disease course. Patients may initially be asymptomatic or present with leucocytosis or thrombocytosis, anaemia, progressive splenomegaly, constitutional symptom, thromboses or accelerated/blastic phase disease. Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU-U. Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative strategy yet outcomes, to date, are not well defined. We hereby report on the largest retrospective study of patients with MPN-U undergoing allo-HCT, highlighting the potentially curative role and providing clinicians with robust engraftment, GvHD and outcome data to facilitate patient discussion.
Предметные рубрики MeSH
AdultAgedDatabases, FactualFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansIncidenceKaplan-Meier EstimateMaleMiddle AgedMutationMyeloproliferative DisordersRecurrenceRetrospective StudiesRiskSocieties, ScientificTransplantation ConditioningTransplantation, HomologousTreatment OutcomeYoung Adult